Neoadjuvant drug study for hormone- and HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 75.
- Your breast cancer test shows it is ER-positive and HER2-positive.
- You have stage II or III breast cancer (not stage IV).
- You have not received any prior anti-cancer treatment for this cancer.
- Your general health is good enough for study treatment (ECOG 0–1).
- Heart function looks strong enough for the study (left-ventricle ejection fraction at least 50%) and your ECG QT is within limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.